West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 22 10 2021 10 01 Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients 3355 3363 89812 10.31557/APJCP.2021.22.10.3355 EN Diya Hasan Al-Balqa Applied University, Zarqa College, Department of Allied Medical Sciences, Zarqa, Jordan. Yazan Ismail Higher Colleges of Technology, Faculty of Health Sciences, Abu Dhabi, United Arab Emirates. Ahmad Al Tibi Biolab Diagnostic Laboratories, Amman, Jordan. Safaa A AL-Zeidaneen Al-Balqa Applied University, Zarqa College, Department of Allied Medical Sciences, Zarqa, Jordan. Mohanad Odeh Hashemite University, Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacy and Pharmacy Practice, Zarqa, Jordan. George J Burghel Manchester University NHS Foundation Trust, Manchester Centre for Genomics Medicine, Manchester, UK. Iyad Natsheh Al-Balqa Applied University, Zarqa College, Department of Allied Medical Sciences, Zarqa, Jordan. Amid Abdelnour Biolab Diagnostic Laboratories, Amman, Jordan. Journal Article 2021 04 27 Objective: This study aimed to investigate level fluctuations of serum biomarkers that are associated with cardiotoxicity risk, such as high-sensitivity C-reactive protein (hs-CRP) and apolipoprotein-B (Apo-B) in response to chemotherapy treatment for breast cancer. Method: The serum levels of hs-CRP and Apo-B were evaluated in 56 breast cancer patients with main inclusion criteria: HER2 negative and who received adjuvant chemotherapy AC [A: Adriamycin, C: Cyclophosphamide] or AC→T [A: Adriamycin, C: Cyclophosphamide, T: Taxane] regimes at early II (n = 26) and late IV (n = 30) clinical stages by using particle enhanced turbidimetric assay. Results: The results of this study suggest that a high level of pre-treatment hs-CRP is a good prognostic marker in comparison to Apo-B. Moreover, the AC-T chemotherapy regime treatment in both early and late stages exhibited a significantly higher level of hs-CRP compared to that in the AC regime. Hs-CRP was significantly elevated in the early stage in comparison to the late stage among cancer patients, meanwhile Apo-B behaved inversely. Furthermore, the results showed that hs-CRP levels were significantly higher in late-stage cancer patients compared with those in early-stage in both chemotherapy regimens groups. On the other hand, Apo-B showed no significant differences. Conclusion: Monitoring hs-CRP level changes in comparison to Apo-B can be used to assist the side effect risk difference among different chemotherapy regimens, and staging reflecting a positive correlation between them more notable in the late stage. https://journal.waocp.org/article_89812_4cf105bbebe1a0809dbbb7b9b72cb151.pdf